[go: up one dir, main page]

PE20050766A1 - Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
PE20050766A1
PE20050766A1 PE2005000081A PE2005000081A PE20050766A1 PE 20050766 A1 PE20050766 A1 PE 20050766A1 PE 2005000081 A PE2005000081 A PE 2005000081A PE 2005000081 A PE2005000081 A PE 2005000081A PE 20050766 A1 PE20050766 A1 PE 20050766A1
Authority
PE
Peru
Prior art keywords
ondasetron
procedures
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
PE2005000081A
Other languages
English (en)
Inventor
Barjoan Pere Dalmases
Carandell Lluis Sola
Olle Francesc Alcobe
Vallet Maria Cristina Puigjaner
Original Assignee
Inke Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34802828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inke Sa filed Critical Inke Sa
Publication of PE20050766A1 publication Critical patent/PE20050766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMA POLIMORFICA C DE ONDANSETRON BASE, CARACTERIZADA POR SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA PICOS CARACTERISTICOS A 14,97° Y 20, 86° 2q Y NO PRESENTA PICOS POR DEBAJO DE 6,5° 2teta . FORMA POLIMORFICA D DE ONDANSETRON BASE CARACTERIZADA POR EL HECHO DE QUE SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA PICOS CARACTERISTICOS A 11,29° ;14,58° ;17,16°; 18,89° ; 20,28°; 21,22°; 25,06° Y 27,49° 2teta. FORMA POLIMORFICA E DE ONDANSETRON BASE CARACTERIZADA POR EL HECHO DE QUE SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA PICOS CARACTERISTICOS A 6,29° ;11,09° ;11,88; 12,69° ; 14,97° Y UN DOBLETE A (24,96°; 25,17°) 2teta. FORMA POLIMORFICA CARACTERIZADA POR EL HECHO DE QUE SU DIFRACTOGRAMA DE RAYOS X EN POLVO PRESENTA ADEMAS UN PICO A 25,50° 2teta
PE2005000081A 2004-01-21 2005-01-20 Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen PE20050766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200400115A ES2238001B1 (es) 2004-01-21 2004-01-21 Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.

Publications (1)

Publication Number Publication Date
PE20050766A1 true PE20050766A1 (es) 2005-12-14

Family

ID=34802828

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000081A PE20050766A1 (es) 2004-01-21 2005-01-20 Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen

Country Status (8)

Country Link
EP (1) EP1709033A1 (es)
JP (1) JP2007518791A (es)
KR (1) KR20060127892A (es)
AR (1) AR047435A1 (es)
ES (1) ES2238001B1 (es)
PE (1) PE20050766A1 (es)
TW (1) TW200528100A (es)
WO (1) WO2005080381A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
DE202007019476U1 (de) 2006-10-02 2013-01-25 Labtec Gmbh Nicht-mucoadhäsive Filmdosisformen
AU2008333845C1 (en) * 2007-12-07 2014-01-16 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
BR112012024092A2 (pt) 2010-03-23 2016-09-06 Bioalliance Pharma filme de rápida dissolução oral
EP2377526A1 (en) 2010-03-23 2011-10-19 BioAlliance Pharma Fast dissolving drug delivery systems
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
BR112016010403A2 (pt) 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85743A1 (fr) * 1984-01-25 1986-08-04 Glaxo Group Ltd Composes heterocycliques
HRP20041136A2 (en) * 2002-04-30 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Novel crystal forms of ondansetron, processes fortheir preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
ES2199061B1 (es) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
FI6164U1 (fi) 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
DE20312772U1 (de) * 2003-08-19 2003-10-30 Synthon Bv Ondansetron-Formen

Also Published As

Publication number Publication date
WO2005080381A1 (en) 2005-09-01
ES2238001A1 (es) 2005-08-01
KR20060127892A (ko) 2006-12-13
JP2007518791A (ja) 2007-07-12
TW200528100A (en) 2005-09-01
ES2238001B1 (es) 2006-11-01
EP1709033A1 (en) 2006-10-11
AR047435A1 (es) 2006-01-18

Similar Documents

Publication Publication Date Title
AR108819A2 (es) Formas polimórficas de un inhibidor macrocíclico de vhc
ZA202007679B (en) Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
AR116052A2 (es) Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
UY33075A (es) Derivados de ciclohexano y usos de los mismos
ATE528989T1 (de) Kristalline feste rasagilin-base
NO20080784L (no) Histondeacetylaseinhibitorer
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
AR047088A1 (es) Polimorfo cristalino de piridinetilennaftofurano como antagonista del receptor de trombina, metodo de obtencion y composiciones farmaceuticas
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CR9954A (es) Derivados de pirazina
CO5580827A2 (es) Forma polimorfa de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
NI201100034A (es) Uso de dronedarona para la preparación de un medicamento para la prevención de ictus o ataque isquémico transitorio.
EP1861358A4 (en) NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
UY33348A (es) Compuestos de furopiridina y usos de los mismos
PE20050766A1 (es) Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.

Legal Events

Date Code Title Description
FD Application declared void or lapsed